The mydriatic effect of topically administered tropicamide was investigated as a possible diagnostic indicator for Alzheimer's disease. Although an initial series seemed to show a correlation between hypersensitivity to tropicamide and intellectual impairment, subsequent testing showed a greater inter-and intra-individual variation than that between the normal group and the group of patients with intellectual impairment. This procedure seems, therefore, to lack sufficient specificity to be useful for such a diagnostic purpose.
INTRODUCTION
have" found a mydriatic hypersensitivity to 0.01% topically administered tropicamide in patients with Down's syndrome, which was attributed to acetylcholinedeficiency. Scinto et al. (1994) have reported such a procedure as a simple diagnostic method for the differential diagnosis of Alzheimer's disease from others causing intellectual impairment.
In this paper, the authors have sought to eliminate all other possible causes of variation in pupillary dilation. Firstly, the effects of agitation, distress, unknown systemicpharmaceuticals,and undetected environmental adaptati,pneffects were eliminated by measuring both pupillary diameters, but administering tropicamide to only one eye. All patients were given a Schirmer's test, tear film break up test, Meibomian gland evaluation, endothelial cell count, corneal pachymetry, intra-ocular pressure measurement and iris colour recorded.
The test was repeated after 4 weeks to assess the reproducibilityof results over time, and an effect due to corneal permeability was eliminated by comparing the effect of tropicamide after oxybuprocainpretreatmenton either eye alternately of three control individuals [see Fig. 6(A, B) ].
SUBJECTSAND METHODS
34 intellectually impaired patients (age 69 i 11) years, 20 male 14 female) were investigated. The onset (1993) ,based on a personal computer receiving data from an infra red sensitive camera (Canon) via an Oculus-OC-300/ 512 x 1024 frame grabber. This recorded the following at a rate of 25 Hz (real time): vertical and horizontal eye movement, accommodation by on-line retinoscopy and pupillary size. Background illuminance was 100 IUX, spatial resolution was 0.1 mm.
Data registrationis halted during blinking for approximately 1.5 sec to avoid pupil changes. The automated data collection is expressed as the, average of 250 measurementscalculated off-line. These on-line controls seem to be necessary to obtain reliable results. After baseline pupil measurement, 0.01% tropicamide was administeredto one eye chosen at random and pupillary 165 measurementswere taken of both eyes at 15 min intervals for 90 min. After an interval of 4 weeks, the tests were repeated in the same way but with both eyes being treated with tropicamide in order to evaluate intra-individual variation.
Written informed consent was obtained from patients and care-givers, respectively.
STATISTICALANALYSIS
Comparing location (mean) and scale (variance) parametrically we used the paired Student's t-test after comparing variances with Fisher's F-test. With the calculation of the Pearson's r product-moment linear correlation coefficient as well as with explorative data analysis we tested the strength of association between tear film parameters, corneal parameters, mind scores, and the dilatoryeffect of tropicamide.In order to evaluate whether the change in pupil diameter is associated with comeal and tear film variables, the multiple correlation coefficientwas calculated.
RESULTS
Tear film and corneal parameters were all within the normal range for elderly individuals ( more, they were not different in the two separate groups of patients. Neither single correlation nor multi-variant analysis showed a correlation of pupil dilation with any of the measured ocular anatomy or physiology. For the intellectually impaired patients, Fig. 1 shows an average YO change in pupil diameter 45 min after tropicamide application of 18.6 t 11.02%. Figure 2 shows that there was little change in the average on the secondvisit and no average difference in the fellow eyes, however, Fig. 3 shows a striking intra-individual variation. Individualresults could show a variation by a factor of 2 between the first and second test in the same eye. Figure 4 compares the results from the two separate groups of those 23 patients confidently diagnosed with AD to those 11 less impaired.On the firstoccasion a clear difference was seen (1'= 0.05; not shown in Fig. 4) , however, on the second test there was no significant difference.
For the normal controls and below 10% were found. Of the control individuals with a dilation of more than 20'%on the first test, eight had values below 10% and three individualsbetween 15 and 2090when tested 4 weeks later. However, a clear-cut influenceof corneal permeability on the response to tropicamide administration could be demonstratedexperimentally:prior to tropicamideapplication healthy controls (n = 3, 37 f 2 yr) received anesthetic eye drops (oxybuprocain 0.4%) three times in 2 min intervals in one eye. Figure 6 (A) shows a 5090 pupil dilation over baseline in such pretreated eyes compared to a discrete dilation of less than 10Yoin the fellow eye. The nonspecific dilating effect due to pretreatment could be verified by repeating the experiments for the other eye [ Fig. 6(B) ].
DISCUSSION
In the patient collectivewe found an average mydriatic effect in the tropicamidetreated eye of 18.6%-similar to the results obtained by Scinto-and FIGURE 6. The influence of corneal permeability on the response to 0.01% tropicamide eye drops is shown. Prior to tropicamide application to both eyes three healthy controls received oxybuprocain eye drops in one eye. Subsequently, infra-red pupillography was performed as described. In such pretreated eyes up to 5070dilation over baseline was observed (A). The nonspecificdilating effect due to pretreatment was verified by repeating the experiments for the other eye (B).
average diameter of the untreated eye. The same results-as regards the average mydriatic effect-were obtained in a second test series performed 4 weeks later.
No differencewas seen between the right and the left eye.
Those patients complaining about memory impairment although passing the MMSE showed less dilating response in the first test series. However, on retesting, this finding could not be reproduced; indicating that at this pointpupillaryresponseto pharmacologicalagents is not able to distinguish diagnosed AD patients from patients complaining about memory impairment but lacking clinically notable cognitive defects. Despite the fact that pupillography was performed under standardized conditions, intra-individualvariation in all subgroupsof patients as well as in control subjects was extremelyhigh, indicatingthat this test is not specific enough. Taking 13Y0of pupil dilation as a cut-off value we would have missed 39?Z0 of diagnosed AD patients, while 67Y0of normal controls would have reacted false positive.
Although the influence on corneal permeability of oxybuprocain [see Fig. 6(A, B) ] altered the effect of tropicamide, no ocular pathologies were found in the subjects tested to account for the large variability in results found between individuals or occasions. Never-theless, the influence of epithelial barrier function and endothelial pump function needs further attention.
All measurements of tear film condition are still imprecise, however, Down's syndrome patients appear (Shapiro & France, 1985) to have anatomical anomalies in the anterior segment (e.g. iris stromal atrophy, keratoconus, blepharitis, nasolacrimal duct obstruction etc.) which may cause a difference in the effect of tropicamide.
The expected differentiationof intellectuallyimpaired from normal individualsdue to a cholinergicdeficitwas not found using this testing method. Further experimentation with alternativepharmaceuticalagents or a testing regime carried out over different time intervalswill have to be conducted before the utility of this simple test of pupillary reaction in the diagnosis of Alzheimer's desease can be determined.
